Avastin Pricing Strategy, Expanded Indications Under Review At Genentech
Executive Summary
Genentech may reconsider pricing forAvastin following "phenomenal" clinical trial results evaluating the biologic for first-line non-squamous non-small cell lung cancer and metastatic breast cancer
You may also be interested in...
Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations
Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use
Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations
Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005